Latest Strategy News

Blue Star Helium has successfully started helium production at its Pinon Canyon plant, marking a key milestone as it prepares for commercial sales and expansion in 2026.

Gratifii Limited is set to transform its digital marketing and engagement capabilities through the acquisition of New Zealand’s Mosh Digital and the Future Pass digital wallet platform, backed by a $2.5 million capital raise.

Reece Limited has increased its on-market share buyback target by $50 million, raising the total to $85 million as part of its disciplined capital management strategy.

High-Tech Metals has intersected visible gold in multiple zones at its Wagtail deposit, advancing drilling and development efforts toward a potential near-term mining decision.

Tartana Minerals has received $1 million from a new investor as part of a $1.275 million placement, setting the stage for debt reduction and upcoming shareholder decisions.

The Northern Finland Administrative Court has overturned Kingsrose Mining’s exploration permit for the Penikat Project due to procedural errors by the regulator, delaying planned drilling until at least April 2026. Kingsrose remains confident in the project’s long-term potential despite the setback.

Finbar Group has conditionally acquired a prime South Perth site for $16.5 million, aiming to launch a $350 million apartment development by 2028 and boosting its pipeline to over $1.6 billion.

Beetaloo Energy’s Carpentaria-5H well has delivered one of the highest gas flow rates in the Beetaloo Basin, showcasing promising long-term productivity and paving the way for pilot gas sales in 2026.

archTIS has renewed 1,000 NC Protect licenses within the U.S. Department of Defense’s Microsoft DoD365 environment and secured an $8 million debt facility to accelerate its U.S. market expansion.

Cann Group Limited has launched a comprehensive suite of option offers aimed at raising incremental capital, subject to shareholder approval at a December 23 meeting. The prospectus outlines potential dilution and financial impacts as the company seeks to strengthen its balance sheet.

Pure One Corporation Limited is set to exit its 40% stake in Turquoise Group for AUD 5 million, securing a substantial profit and refocusing on its core clean energy ventures.

BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics for US$4.8 billion includes Dimerix’s US licensing agreement, promising significant milestone payments and royalties. This deal strengthens Dimerix’s position as it advances its Phase 3 kidney disease therapy.